-
New Forum Software Installed (Still a few issues but reopening the forum) More details.
ARC institute launches—includes Stanford, Berkeley
- Thread starter Jaybee00
- Start date
-
- Tags
- arc institute
rvallee
Senior Member (Voting Rights)
Arc gives scientists no-strings-attached, multi-year funding, so that they don’t have to apply for external grants, and invests in the rapid development of experimental and computational technological tools.
As individuals, Arc researchers collaborate across diverse disciplines to study complex diseases, including cancer, neurodegeneration, and immune dysfunction. As an organization, Arc strives to enable ambitious, long-term research agendas.
Arc’s mission is to accelerate scientific progress, understand the root causes of disease, and narrow the gap between discoveries and impact on patients.
As individuals, Arc researchers collaborate across diverse disciplines to study complex diseases, including cancer, neurodegeneration, and immune dysfunction. As an organization, Arc strives to enable ambitious, long-term research agendas.
Arc’s mission is to accelerate scientific progress, understand the root causes of disease, and narrow the gap between discoveries and impact on patients.
Sounds great and applicable here. Let's hope this is a real mission statement and not a feel-good slogan or marketing pitch. If they want to make a splash, solving one of the biggest scientific puzzles in history sounds like a great start. Unless they're chicken, that is. Buck-buck-buckaaah!
Snow Leopard
Senior Member (Voting Rights)
What does this mean for less popular areas like ME/CFS or LongCovid? Or is this just easier access for more popular diseases to be researched?
rvallee
Senior Member (Voting Rights)
So just regular dinosaurs, then? One does have to place limits on suspension of disbelief. Time travel? Pffft.
Wonko
Senior Member (Voting Rights)
https://www.liebertpub.com/doi/10.1089/genbio.2022.29017.jgr
A bold new nonprofit research institute in Palo Alto, California, infuses uniquely funded core investigators, biotech-inspired technology centers, and academic partnerships to solve complex diseases.
Taking root on the Stanford campus in Palo Alto, CA, Arc's research biome, supported by $650 million in initial funding, will consist of four main elements: (1) long-term funded core investigators (not tied to a specific project), (2) multidisciplinary experts in one physical laboratory, (3) biotech-inspired technology centers, and (4) partnerships with academic institutions such as Stanford, University of California San Francisco (UCSF), and UC Berkeley.
This is not the first time we have seen a combination of curiosity-driven science (modeled best by the university system), multidisciplinary experts under one roof (institutes such as the Broad do this well today), scientific infrastructure, tools (normally seen in a biotech), and almost unconstrained funding, working together to push the scientific progress pedal to the metal. (There are some similarities to the model of the Howard Hughes Medical Institute [HHMI], which employs ∼270 biomedical investigators in a people-not-projects approach to conduct “risky” research.)
Arc aims to flourish by nurturing the early noncommercial preclinical stage of discovery pertaining to complex diseases such as Alzheimer's, as opposed to casting a wider net on human health and treating disease such as the Chan Zuckerberg Initiative or similar recent endeavors that have a broader biology and engineering slant (Box 1).
To ensure that discoveries at Arc that are medically relevant (such as key disease pathways and targets) actually make an impact on patients, the nonprofit plans to provide translational support: a faster IP licensing process, finance assistance, and a drug development and expert advisory network. Arc will also form targeted entrepreneurial teams committed to exploring specific concepts, such as a new gene target or effector chemical. Ultimately, the mission is to enable Arc scientists, engineers, and innovators to translate their research into tangible benefits for patients with complex disease.
A bold new nonprofit research institute in Palo Alto, California, infuses uniquely funded core investigators, biotech-inspired technology centers, and academic partnerships to solve complex diseases.
Taking root on the Stanford campus in Palo Alto, CA, Arc's research biome, supported by $650 million in initial funding, will consist of four main elements: (1) long-term funded core investigators (not tied to a specific project), (2) multidisciplinary experts in one physical laboratory, (3) biotech-inspired technology centers, and (4) partnerships with academic institutions such as Stanford, University of California San Francisco (UCSF), and UC Berkeley.
This is not the first time we have seen a combination of curiosity-driven science (modeled best by the university system), multidisciplinary experts under one roof (institutes such as the Broad do this well today), scientific infrastructure, tools (normally seen in a biotech), and almost unconstrained funding, working together to push the scientific progress pedal to the metal. (There are some similarities to the model of the Howard Hughes Medical Institute [HHMI], which employs ∼270 biomedical investigators in a people-not-projects approach to conduct “risky” research.)
Arc aims to flourish by nurturing the early noncommercial preclinical stage of discovery pertaining to complex diseases such as Alzheimer's, as opposed to casting a wider net on human health and treating disease such as the Chan Zuckerberg Initiative or similar recent endeavors that have a broader biology and engineering slant (Box 1).
To ensure that discoveries at Arc that are medically relevant (such as key disease pathways and targets) actually make an impact on patients, the nonprofit plans to provide translational support: a faster IP licensing process, finance assistance, and a drug development and expert advisory network. Arc will also form targeted entrepreneurial teams committed to exploring specific concepts, such as a new gene target or effector chemical. Ultimately, the mission is to enable Arc scientists, engineers, and innovators to translate their research into tangible benefits for patients with complex disease.
https://twitter.com/user/status/1878871035631865886
Today, Arc announced it is joining forces with @NVIDIAHealth to develop powerful computational tools that will help researchers everywhere explore and understand living systems in ways previously impossible.
Today, Arc announced it is joining forces with @NVIDIAHealth to develop powerful computational tools that will help researchers everywhere explore and understand living systems in ways previously impossible.
https://twitter.com/user/status/1923796683537907907
Arc is hiring a Chief Scientific Officer! Come work with at what I think is the most dynamic and ambitious biology research organization in the world, partnering with @pdhsu, @SKonermann, @davey_burke, Arc's extraordinary faculty, and many more.
https://twitter.com/user/status/1924055950463262806
There are few jobs where you could have more effect on the world, or work with better people, than this one.
Arc is hiring a Chief Scientific Officer! Come work with at what I think is the most dynamic and ambitious biology research organization in the world, partnering with @pdhsu, @SKonermann, @davey_burke, Arc's extraordinary faculty, and many more.
https://twitter.com/user/status/1924055950463262806
There are few jobs where you could have more effect on the world, or work with better people, than this one.